MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Revue du Rhumatisme
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

109 results · 1 filter active ·
Results by year
20012025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
109 works in the cohort · of 4,299,418page 1 of 3

Labels cover 0 of 109 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 109 of 109 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affno abstractunlabeled
Soulager le mal de dos
B Naveau
2001· article· fr· Revue du Rhumatisme· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
Physiopathologie de l’ostéodystrophie rénale
Fabrice Mac Way, Myriam Lessard, Marie‐Hélène Lafage‐Proust
2012· article· fr· Revue du Rhumatisme· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
fundno affno abstractunlabeled
Microbiote et os
Lidia Ibáñez, Matthieu Rouleau, Abdelilah Wakkach, Claudine Blin‐Wakkach
2018· article· fr· Revue du Rhumatisme· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Génétique de l’arthrose digitale
Laëtitia Michou
2010· article· fr· Revue du Rhumatisme· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Le bimékizumab améliore la qualité de vie chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo
Laure Gossec, Dafna D. Gladman, Lars Erik Kristensen, Diamant Thaçi, Paolo Gisondi, M. Elaine Husni +8 more
2022· article· fr· Revue du Rhumatisme· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
L’aprémilast, un inhibiteur oral de la phosphodiestérase 4, est associé à une amélioration à long terme (104 sem.) de la fatigue chez les patients atteints de rhumatisme psoriasique : résultats regroupés de 3 études de phase III, contrôlées, randomisées
Arthur Kavanaugh, Dafna D. Gladman, C.J. Edwards, P. Airi, Frédéric Lioté, Paul Bird +4 more
2016· article· fr· Revue du Rhumatisme· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Lésions osseuses d’un syndrome POEMS
Cyrielle Genicon, L. Guilloton, Michel Pavic, François Le Moigne
2022· article· fr· Revue du Rhumatisme· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Améliorations cliniquement significatives des critères-patient sous guselkumab chez les patients atteints de rhumatisme psoriasique actif en réponse inadéquate aux anti-TNF : résultats à un an d’une étude de phase 3b, randomisée, contrôlée (COSMOS)
Laure Gossec, Xenofon Baraliakos, James Galloway, Lars Erik Kristensen, V. Oke, Petros P. Sfikakis +4 more
2023· article· fr· Revue du Rhumatisme· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
next →

How this was built: Screen · Findings · About